^
Association details:
| Biomarker: | HER-2 exon 20 YVMA insertion |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Exkivity (mobocertinib) (EGFR inhibitor, HER2 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Targeting HER2 Exon 20 Insertion–Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib
Published date:
10/15/2021
Excerpt:
In the HER2 exon 20G776>VC–mutant GEMM model, mobocertinib dosed at 30 mpk demonstrated a rapid tumor regression after just 2 weeks of treatment with close to complete response after 4 weeks of treatment...HER2 exon 20YVMA GEMM initially responded to mobocertinib but became acquired resistant upon continuous treatment...
DOI:
10.1158/0008-5472.CAN-21-1526
